IDEXX Q3 revenue $810M (+12%), EPS $2.03; raises FY2021 guidance to higher end

IDEXX LABORATORIES INC /DE

2021-Q3 EPS reported $6.71 revenue$2,414,270,000

Q3 revenue $810M (+12% reported, +10% organic); EPS $2.03 (+20% reported, +12% comparable).
CAG Diagnostics recurring revenue +13% reported, +11% organic; record Q3 premium instrument placements.
Updates FY2021 guidance: revenue $3,185-3,200M (17.5-18% growth), EPS $8.30-8.38 (24-25% growth).
Operating margin 27.9% (+410bps reported, +20bps comparable); benefited from lapping prior year litigation accrual.
Water revenue +15% reported, +13% organic; LPD revenue declined 21% due to China ASF testing comparison.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.